Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Yonsei University

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Private

Established: 1885-01-01

Employees: 5K

Market Cap: -

Website: http://www.yonsei.ac.kr

Clinical Trials

Dose Finding Study of Remimazolam for Laryngeal Mask Airway Insertion

Not Applicable

Conditions: Orthopedic Surgery

Interventions: Drug: Remimazolam bolus does administration

First Posted Date: 2022-03-28

Last Posted Date: 2022-03-28

Lead Sponsor: Yonsei University

Target Recruit Count: 25

Registration Number: NCT05298228

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients

Phase 2

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: paclitaxel/carboplatin

First Posted Date: 2022-03-24

Last Posted Date: 2022-03-25

Lead Sponsor: Yonsei University

Target Recruit Count: 79

Registration Number: NCT05294900

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Comparison of the Clinical Performance and Safety of the Ambu®AuraGainTM Laryngeal Mask in Children Undergoing Surgery in the Supine and Prone Position - A Prospective, Noninferiority Clinical Trial

Completed

Conditions: Bone Marrow Examination
Urologic Surgical Procedures
Orthopedic Surgery

First Posted Date: 2022-03-18

Last Posted Date: 2024-06-06

Lead Sponsor: Yonsei University

Target Recruit Count: 126

Registration Number: NCT05286021

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: GX-188E, Pembrolizumab
Drug: GX-188E, GX-I7, Pembrolizumab
Drug: GX-188E, GX-I7

First Posted Date: 2022-03-18

Last Posted Date: 2025-06-15

Lead Sponsor: Yonsei University

Target Recruit Count: 56

Registration Number: NCT05286060

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Comparison of Quality of Recovery Between Remimazolam and Propofol Anesthesia in Patients Undergoing Arthroscopic Meniscectomy

Not Applicable

Completed

Conditions: Adult Patients 19 or Older Scheduled for Elective Arthroscopic Meniscectomy

Interventions: Drug: Propofol TIVA
Drug: Remimazolam TIVA

First Posted Date: 2022-03-15

Last Posted Date: 2024-07-08

Lead Sponsor: Yonsei University

Target Recruit Count: 80

Registration Number: NCT05280236

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: nivolumab-GX-188E-GX-I7

First Posted Date: 2022-03-15

Last Posted Date: 2023-03-28

Lead Sponsor: Yonsei University

Target Recruit Count: 21

Registration Number: NCT05280457

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Catheter-directed Sclerotherapy Versus Surgical Resecction: Randomized Controlled Trial Comparing Ovarian Function and Therapeutic Efficacy After Treatment of Ovarian Endometrioma

Not Applicable

Conditions: Ovarian Endometrioma

Interventions: Procedure: catheter-directed sclerotherapy
Procedure: surgical resection

First Posted Date: 2022-03-15

Last Posted Date: 2022-03-15

Lead Sponsor: Yonsei University

Target Recruit Count: 98

Registration Number: NCT05279209

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations

Phase 2

Not yet recruiting

Conditions: NSCLC

Interventions: Drug: Lazertinib

First Posted Date: 2022-03-14

Last Posted Date: 2022-03-14

Lead Sponsor: Yonsei University

Target Recruit Count: 36

Registration Number: NCT05277701

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial

Phase 2

Conditions: HER2-positive Gastric Cancer

Interventions: Drug: Tislelizumab+Zanidatamab

First Posted Date: 2022-03-08

Last Posted Date: 2022-03-08

Lead Sponsor: Yonsei University

Target Recruit Count: 50

Registration Number: NCT05270889

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Nivolumab for Recurrent/Metastatic Carcinosarcoma

Phase 2

Conditions: Recurrent/Metastatic Carcinosarcoma

Interventions: Drug: nivolumab

First Posted Date: 2022-02-04

Last Posted Date: 2022-02-04

Lead Sponsor: Yonsei University

Target Recruit Count: 28

Registration Number: NCT05224999

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy